Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Individualizovaná komplexní léčba pokročilého hepatocelulárního karcinomu (ICT-HCC)

28. září 2026 aktualizováno: Nanjing Tianyinshan Hospital

Průzkumná kohortová studie a mechanistický výzkum individualizované komplexní léčby po standardní léčbě pokročilého hepatocelulárního karcinomu

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

270

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210000
        • Nábor
        • China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age ≥18 years old, male or female
  2. Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
  3. Clinical disease progression after first-line targeted combined immune system therapy (PD-1 or PD-L1 monoclonal antibody only)
  4. Life expectancy exceeds 3 months
  5. ECOG physical condition score 0~1
  6. Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to contraception within 24 weeks from the date of signing the informed consent to the last administration of the study drug
  7. Before the first dose of the investigational drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥ 2.0 × 109/L; platelet (PLT) ≥ 60× 109/L; hemoglobin content (HGB) ≥ 8.0 g/dL; ② Liver function: aspartate transferase (AST) ≤ 2.5x ULN; alanine aminotransferase (ALT) ≤ 2.5 x ULN; Serum total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert syndrome total bilirubin ≤ 3.0 mg/dL); ③ Renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance rate (CrCl) ≥ 50 mL/minute; ④ Coagulation function: international normalized ratio (INR) ≤ 1.5 x ULN, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (only for patients who are not currently receiving anticoagulant therapy, patients who are currently receiving anticoagulant therapy should receive a steady dose of anticoagulant therapy)
  8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up

Exclusion Criteria:

  1. Pathological types of other non-hepatocellular carcinomas, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc. previously confirmed by histology/cytology
  2. Child-Pugh grade of liver function> 7 points
  3. Major cardiovascular impairment in the 6 months prior to initial administration of the drug, such as a New York Heart Association (NYHA) Class II or higher history of congestive heart failure, unstable angina, myocardial infarction or stroke, or arrhythmia associated with hemodynamic instability; Corrected QT (QTc) interval lengthening >480ms
  4. Other malignancies developed ≤ 5 years before the first dose, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery (hormone therapy for non-metastatic prostate cancer or breast cancer is allowed)
  5. Have had an active autoimmune disease in the past 2 years that requires systemic treatment, including but not limited to autoimmune hepatitis, lupus erythematosus, etc
  6. Uncontrolled active infection, such as active tuberculosis, HIV infection, etc.; Patients with HBV-DNA replication level below 10000IU/mL and continuous oral antiviral therapy could be enrolled.
  7. Had undergone major surgery in the 28 days prior to randomization or planned to undergo major surgery during the study period
  8. Use of live attenuated vaccine within 28 days prior to randomization, or anticipated use of such live attenuated vaccine during the study period (patients are not allowed to receive live attenuated influenza vaccine 4 weeks prior to randomization, during treatment, and within 5 months after the final administration of adbelizumab)
  9. Received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF
  10. Use of corticosteroids (> 10 mg/ day prednisone or equivalent dose) or other immunosuppressants within ≤ 14 days prior to the first dose of the study drug. Allowing inhaled or topical use of steroids and adrenal replacement steroids in the absence of active autoimmune disease; Patients received systemic immunosuppressive drugs (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] drugs) within 1 week prior to randomization. Patients receiving short-term, systemic immunosuppressant therapy, such as glucocorticoids for nausea, vomiting, or anaphylaxis management or prevention, may be enrolled in the study after investigator review. To allow the use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease, corticosteroids such as fluhydrocortisone in patients with postural hypotension, and low-dose glucocorticoid supplements for adrenal insufficiency; Known mental illness, alcoholism, inability to quit smoking, drug or substance abuse
  11. In the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious illnesses (including mental illness) requiring combined treatment, serious laboratory abnormalities, family or social factors that may affect the safety of the subjects, or the collection of data and samples

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm 1

XELOX/FOLFOX4+ Adebelizumab + Apatinib+Icaritin

FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

Experimentální: Arm 2

Adebelizumab + Apatinib+Icaritin

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Experimentální: Arm 3a

QL1706+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimentální: Arm 3b

Retlirafusp alfa+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimentální: Arm 4

The original targeted combination immunotherapy+HAIC

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Hepatic Arterial Infusion Chemotherapy

Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

Experimentální: Arm 5a

QL1706+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimentální: Arm 5b

Retlirafusp alfa+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimentální: Arm 6a

QL1706+Bevacizumab+Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

Experimentální: Arm 6b

Retlirafusp alfa+Bevacizumab+Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
PFS(Progression-free Survival)
Časové okno: 24 months

Progression-free survival (PFS) was defined as the time from treatment initiation on Day 1 to the earliest occurrence of radiologically confirmed disease progression, as assessed by tumor imaging, or death from any cause, whichever came first. Evaluations were conducted by the investigator in accordance with RECIST v1.1.

24 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
OS(Overall survival)
Časové okno: 48 months

Overall survival (OS) was defined as the duration from treatment initiation on Day 1 to death from any cause.

48 months
ORR(Objective response rate)
Časové okno: 24 months

Objective response rate (ORR) was defined as the proportion of subjects achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

24 months
DCR(Disease control rate )
Časové okno: 24 months

Disease control rate (DCR) was defined as the proportion of subjects achieving a complete response (CR), partial response (PR), or stable disease (SD) lasting ≥8 weeks, as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

24 months
DOR(Duration of Response)
Časové okno: 24 months

Duration of response (DOR) was defined as the time from the first documented objective response (CR or PR) to the earliest occurrence of radiological disease progression or death from any cause, whichever occurred first. Both response and progression were evaluated by the investigator according to RECIST v1.1.

24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

22. května 2025

Primární dokončení (Odhadovaný)

15. prosince 2027

Dokončení studie (Odhadovaný)

15. prosince 2028

Termíny zápisu do studia

První předloženo

27. února 2025

První předloženo, které splnilo kritéria kontroly kvality

23. března 2025

První zveřejněno (Aktuální)

25. března 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

1. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

28. září 2026

Naposledy ověřeno

1. března 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit